Table 4.
Clinical success for patient-episode-isolate events treated with fluconazole, voriconazole, or itraconazole by their respective CLSI MIC interpretive categories for Candida spp.
| Antifungal agent | MIC breakpoint interpretive category (μg/ml) | No. of events | % success |
|---|---|---|---|
| Fluconazolea | Susceptible (≤2 μg/ml) | 550 | 92 |
| Resistant (≥8 μg/ml) | 212 | 37 | |
| Voriconazoleb | Susceptible (≤0.12 μg/ml) | 173 | 76 |
| Resistant (≥1 μg/ml) | 8 | 38 | |
| Itraconazolec | Susceptible (≤0.12 μg/ml) | 103 | 88 |
| Resistant (≥1 μg/ml) | 6 | 67 |
a
Data compiled from Pfaller et al. (65) for C. albicans, C. tropicalis, and C. parapsilosis.
b
Data compiled from Pfaller et al. (69) for C. albicans, C. tropicalis, and C. parapsilosis.
c
Data compiled from Rex et al. (83) for C. albicans and patient isolates for which plasma concentrations of itraconazole were >0.5 μg/ml.